UCB PHARMA SA

UCB PHARMA SA logo
🇧🇪Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home
Clinical Trials
Related News

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Rotigotine
First Posted Date
2008-01-15
Last Posted Date
2014-10-02
Lead Sponsor
UCB Pharma
Target Recruit Count
124
Registration Number
NCT00593606

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Phase 4
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Certolizumab pegol
Other: Placebo
First Posted Date
2007-12-27
Last Posted Date
2018-08-02
Lead Sponsor
UCB Pharma
Target Recruit Count
333
Registration Number
NCT00580840

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Not Applicable
Completed
Conditions
Memory Disorders
First Posted Date
2007-12-04
Last Posted Date
2013-12-16
Lead Sponsor
UCB Pharma
Target Recruit Count
676
Registration Number
NCT00567060

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

First Posted Date
2007-11-01
Last Posted Date
2018-08-09
Lead Sponsor
UCB Pharma
Target Recruit Count
439
Registration Number
NCT00552058

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Phase 2
Completed
Conditions
Partial Epilepsies
Interventions
Drug: lacosamide
First Posted Date
2007-11-01
Last Posted Date
2018-07-17
Lead Sponsor
UCB Pharma
Target Recruit Count
370
Registration Number
NCT00552305

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2007-10-24
Last Posted Date
2013-09-04
Lead Sponsor
UCB Pharma
Target Recruit Count
220
Registration Number
NCT00548834

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Phase 3
Completed
Conditions
Painful Diabetic Neuropathy
Interventions
Drug: Lacosamide
First Posted Date
2007-10-18
Last Posted Date
2023-09-21
Lead Sponsor
UCB Pharma
Target Recruit Count
621
Registration Number
NCT00546351
Locations
🇧🇪

004, Roeselare, Belgium

🇧🇪

002, Genk, Belgium

🇧🇪

005, Merksem, Belgium

and more 98 locations

Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old

Phase 2
Completed
Conditions
Epilepsy
First Posted Date
2007-10-16
Last Posted Date
2013-11-15
Lead Sponsor
UCB Pharma
Target Recruit Count
13
Registration Number
NCT00544050

Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects

Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
First Posted Date
2007-10-16
Last Posted Date
2013-12-16
Lead Sponsor
UCB Pharma
Target Recruit Count
570
Registration Number
NCT00544388

A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

Phase 2
Completed
Conditions
Absence Seizures
First Posted Date
2007-10-16
Last Posted Date
2013-09-17
Lead Sponsor
UCB Pharma
Target Recruit Count
4
Registration Number
NCT00545012
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy